Last reviewed · How we verify

Active topical NS2 1% dermatologic cream

Aldeyra Therapeutics, Inc. · Phase 2 active Small molecule

Active topical NS2 1% dermatologic cream works by targeting the underlying cause of inflammation in the skin.

Active topical NS2 1% dermatologic cream works by targeting the underlying cause of inflammation in the skin. Used for Treatment of dry eye disease.

At a glance

Generic nameActive topical NS2 1% dermatologic cream
SponsorAldeyra Therapeutics, Inc.
Drug classTopical anti-inflammatory
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 2

Mechanism of action

The exact molecular target of NS2 is not well-documented, but it is believed to modulate the immune response and reduce inflammation in the skin. This is achieved through a complex interplay of cellular and molecular mechanisms that are not yet fully understood.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: